Company intelligence / Profile preview

MBM

Ningbo, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

My-BioMed (MBM) is a precision medicine organization based in Ningbo, China, dedicated to bridging global innovation in the Chinese healthcare market. Established in 2016, the company focuses on providing personalized diagnostic solutions and building an integrated commercialization platform for innovative medical technologies. MBM has formed strategic partnerships with international entities, such as Oxford Cancer Biomarkers, to launch advanced diagnostic suites for colorectal cancer and other oncology indications. The company's expertise spans clinical development, regulatory strategy, and clinical laboratory services, aiming to tailor global precision medicine offerings to the specific needs of the Chinese population.

Therapeutic areas: Oncology
Modalities: Diagnostic test
Industry: Protein Biomarker Diagnostics

Partnerships

Oxford Cancer Biomarkers

Beyond the preview

Go deeper on MBM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBM.

Explore the full profile